The Clinical Evolution of Diffuse Myocardial Fibrosis in Patients With Arterial Hypertension and Heart Failure With Mildly Reduced Ejection Fraction Treated by Olmesartan or Sacubitril / Valsartan

Aim      A 12-month evaluation of the potentialities of the angiotensin II receptor inhibitor olmesartan (Olme) and the angiotensin receptor and neprilysin inhibitor (ARNI) sacubitril/valsartan in patients with arterial hypertension (AH) and dyslipidemia in the dynamics of the following indicators of chronic heart failure (CHF): N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), LV global longitudinal strain (LV GLS) in diffuse myocardial fibrosis (MF) previously diagnosed by magnetic resonance imaging (MRI).

Material and methods  Olmesartan medoxomil (n=56) and sacubitril/valsartan (n=63) were used for 12 months in patients with hypertension, dyslipidemia and NYHA functional class II-III CHF with mid-range LVEF (CHFmrEF). MF was diagnosed by the following MRI criteria: late gadolinium enhancement and an increased proportion of extracellular matrix (33% or more). The frequency of persisting late gadolinium enhancement and the increased proportion of extracellular matrix (33% or more) was evaluated at 12 months; changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), NT-proBNP, and LV GLS were evaluated after 3, 6, and 12 months of follow-up.

Results Baseline parameters did not differ between groups. The late gadolinium enhancement and increased proportion of extracellular matrix were present at baseline in all patients of both groups (100%; p=1.0). Already at 3 months, statistically significant decreases in SBP and DBP were observed in both groups. In addition, the LV GLS monitoring showed LV GLS significantly increased in both groups after 3 months and continued changing after 6 and 12 months. The NT-proBNP concentration significantly decreased in both groups already after 3 months and continued to decrease after 6 and 12 months. At 6 and 12 months, sacubitril/valsartan was superior to olmesartan in reducing SBP and NT-proBNP and in restoring LV GLS. At 12 months, the incidence of persisting, abnormal late gadolinium enhancement and increased proportion of extracellular matrix was significantly less in the ARNI group.

Conclusion      Olmesartan was demonstrated effective in the multi-modality therapy of CHFmrEF and MF in patients with AH and dyslipidemia. ARNI was superior to olmesartan in this regard, but further research of this issue is required.

1. Kade A.Kh., Polyakov P.P., Muratova A.Yu., Bogdanova Yu.A., Vcherash nyuk S.P., Turovaya A.Yu. et al. Mechanisms of myocardial fibrosis. Modern Problems of Science and Education. 2021;2:192. DOI: 10.17513/spno.30609

2. Karamitsos TD, Arvanitaki A, Karvounis H, Neubauer S, Ferreira VM. Myocardial Tissue Characterization and Fibrosis by Imaging. JACC: Cardiovascular Imaging. 2020;13(5):1221–34. DOI: 10.1016/j.jcmg.2019.06.030

3. Barton AK, Tzolos E, Bing R, Singh T, Weber W, Schwaiger M et al. Emerging molecular imaging targets and tools for myocardial fibrosis detection. European Heart Journal - Cardiovascular Imaging. 2023;24(3):261–75. DOI: 10.1093/ehjci/jeac242

4. Lewandowski D, Yang EY, Nguyen DT, Khan MA, Malahfji M, El Tallawi C et al. Relation of Left Ventricular Diastolic Function to Global Fibrosis Burden: Implications for Heart Failure Risk Stratification. JACC: Cardiovascular Imaging. 2023;16(6):783–96. DOI: 10.1016/j.jcmg.2022.12.027

5. Lurz JA, Luecke C, Lang D, Besler C, Rommel K-P, Klingel K et al. CMR–Derived Extracellular Volume Fraction as a Marker for Myocardial Fibrosis. JACC: Cardiovascular Imaging. 2018;11(1):38–45. DOI: 10.1016/j.jcmg.2017.01.025

6. Golukhova E.Z., Aleksandrova S.A., Berdibekov B.Sh. Predictive role of quantification of myocardial fibrosis using delayed contrast-enhanced magnetic resonance imaging in nonischemic dilated cardiomyopathies: a systematic review and meta-analysis. Russian Journal of Cardiology. 2021;26(12):189–97. DOI: 10.15829/1560-4071-2021-4776

7. González A, Schelbert EB, Díez J, Butler J. Myocardial Interstitial Fibrosis in Heart Failure. Biological and Translational Perspectives. Journal of the American College of Cardiology. 2018;71(15):1696–706. DOI: 10.1016/j.jacc.2018.02.021

8. Zaitsev V.V., Gurshchenkov A.V., Mitrofanova L.B., Ryzhkov A.V., Kazakova E.E., Badaev K.D. et al. Clinical significance of different assesment methods of myocardial fibrosis in patients with hypertrophic cardiomyopathy. Kardiologiia. 2020;60(3):44–50. DOI: 10.18087/cardio.2020.3.n561

9. Berdibekov B.Sh., Aleksandrova S.A., Golukhova E.Z. Quantitative assessment of myocardial fibrosis using delayed contrast-enhanced magnetic resonance imaging in noncoronarogenic ventricular arrhythmias. Creative Cardiology. 2021;15(3):342–53. DOI: 10.24022/1997-3187-2021-15-3-342-353

10. Zagrosek A, Abdel-Aty H, Boyé P, Wassmuth R, Messroghli D, Utz W et al. Cardiac Magnetic Resonance Monitors Reversible and Irreversible Myocardial Injury in Myocarditis. JACC: Cardiovascular Imaging. 2009;2(2):131–8. DOI: 10.1016/j.jcmg.2008.09.014

11. Golukhova E.Z., Alexandrova S.A., Bulaeva N.I., Mrikaev D.V., Gromova O.I., Berdibekov B.Sh. Prognostic value of myocardial strain by magnetic resonance imaging in nonischemic dilated cardiomyopathy: a systematic review and meta-analysis. Kardiologiia. 2022;62(10):35–41. DOI: 10.18087/cardio.2022.10.n2034

12. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiological Reviews. 2007;87(4):1285–342. DOI: 10.1152/physrev.00012.2007

13. Song K, Nam Y-J, Luo X, Qi X, Tan W, Huang GN et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature. 2012;485(7400):599–604. DOI: 10.1038/nature11139

14. Dimas V, Ayers C, Daniels J, Joglar JA, Hill JA, Naseem RH. Spironolactone Therapy is Associated with Reduced Ventricular Tachycardia Rate in Patients with Cardiomyopathy. Pacing and Clinical Electrophysiology. 2011;34(3):309–14. DOI: 10.1111/j.1540-8159.2010.02888.x

15. Lee T-M, Lin M-S, Chou T-F, Chang N-C. Additive effects of combined blockade of AT 1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats. American Journal of Physiology-Heart and Circulatory Physiology. 2006;291(3):H1281–9. DOI: 10.1152/ajpheart.00792.2005

16. Piña IL, Camacho A, Ibrahim NE, Felker GM, Butler J, Maisel AS et al. Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. JACC: Heart Failure. 2021;9(1):42–51. DOI: 10.1016/j.jchf.2020.09.012

17. Cheung DG, Aizenberg D, Gorbunov V, Hafeez K, Chen C, Zhang J. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study. The Journal of Clinical Hypertension. 2018;20(1):150–8. DOI: 10.1111/jch.13153

18. Jo S, Moon H, Park K, Sohn C-B, Kim J, Kwon Y-S et al. Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial. Trials. 2022;23(1):36. DOI: 10.1186/s13063-021-05970-7

19. Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. Hypertension Research. 2022;45(5):824–33. DOI: 10.1038/s41440-021-00819-7

20. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599–726. DOI: 10.1093/eurheartj/ehab368

21. Lee V, Zheng Q, Toh D-F, Pua CJ, Bryant JA, Lee C-H et al. Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded end-point clinical trial protocol. Frontiers in Cardiovascular Medicine. 2023;10:1248468. DOI: 10.3389/fcvm.2023.1248468

22. Díez J, Querejeta R, López B, González A, Larman M, Martínez Ubago JL. Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients. Circulation. 2002;105(21):2512–7. DOI: 10.1161/01.CIR.0000017264.66561.3D